FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309595582> ?p ?o ?g. }

• W4309595582 endingPage "133" @default.
• W4309595582 startingPage "118" @default.
• W4309595582 abstract "We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)-negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment.CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy. This article is highlighted in the In This Issue feature, p. 101." @default.
• W4309595582 created "2022-11-28" @default.
• W4309595582 creator A5000653097 @default.
• W4309595582 creator A5003948996 @default.
• W4309595582 creator A5007235827 @default.
• W4309595582 creator A5008019757 @default.
• W4309595582 creator A5008558372 @default.
• W4309595582 creator A5009175382 @default.
• W4309595582 creator A5011478481 @default.
• W4309595582 creator A5012849017 @default.
• W4309595582 creator A5013669743 @default.
• W4309595582 creator A5013973044 @default.
• W4309595582 creator A5019606962 @default.
• W4309595582 creator A5020849158 @default.
• W4309595582 creator A5027604898 @default.
• W4309595582 creator A5028857720 @default.
• W4309595582 creator A5029801761 @default.
• W4309595582 creator A5029945341 @default.
• W4309595582 creator A5031077172 @default.
• W4309595582 creator A5033469242 @default.
• W4309595582 creator A5035811221 @default.
• W4309595582 creator A5035854365 @default.
• W4309595582 creator A5040803891 @default.
• W4309595582 creator A5041561013 @default.
• W4309595582 creator A5044330314 @default.
• W4309595582 creator A5047907485 @default.
• W4309595582 creator A5052469793 @default.
• W4309595582 creator A5058299188 @default.
• W4309595582 creator A5060818260 @default.
• W4309595582 creator A5063117105 @default.
• W4309595582 creator A5070198158 @default.
• W4309595582 creator A5073340860 @default.
• W4309595582 creator A5074555611 @default.
• W4309595582 creator A5076625662 @default.
• W4309595582 creator A5076793020 @default.
• W4309595582 creator A5078736500 @default.
• W4309595582 creator A5079266684 @default.
• W4309595582 creator A5082042235 @default.
• W4309595582 creator A5086683313 @default.
• W4309595582 creator A5090569264 @default.
• W4309595582 creator A5091612581 @default.
• W4309595582 date "2022-11-21" @default.
• W4309595582 modified "2023-10-17" @default.
• W4309595582 title "Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy" @default.
• W4309595582 cites W1647507681 @default.
• W4309595582 cites W2002048624 @default.
• W4309595582 cites W2022990363 @default.
• W4309595582 cites W2054326876 @default.
• W4309595582 cites W2118796952 @default.
• W4309595582 cites W2144728882 @default.
• W4309595582 cites W2161246044 @default.
• W4309595582 cites W2167550136 @default.
• W4309595582 cites W2220044881 @default.
• W4309595582 cites W2342262657 @default.
• W4309595582 cites W2486629951 @default.
• W4309595582 cites W2579739608 @default.
• W4309595582 cites W2604776612 @default.
• W4309595582 cites W2766229434 @default.
• W4309595582 cites W2789780246 @default.
• W4309595582 cites W2802967321 @default.
• W4309595582 cites W2807637103 @default.
• W4309595582 cites W2905654445 @default.
• W4309595582 cites W2924578117 @default.
• W4309595582 cites W2965223724 @default.
• W4309595582 cites W2967175237 @default.
• W4309595582 cites W2992389962 @default.
• W4309595582 cites W3024276903 @default.
• W4309595582 cites W3038604698 @default.
• W4309595582 cites W3127802833 @default.
• W4309595582 cites W3131401867 @default.
• W4309595582 cites W3133229959 @default.
• W4309595582 cites W3137080293 @default.
• W4309595582 cites W3173305141 @default.
• W4309595582 cites W3176532045 @default.
• W4309595582 cites W3191792069 @default.
• W4309595582 cites W3216256147 @default.
• W4309595582 cites W4200593773 @default.
• W4309595582 cites W4220921975 @default.
• W4309595582 cites W4220987987 @default.
• W4309595582 cites W4281628749 @default.
• W4309595582 cites W4281714381 @default.
• W4309595582 cites W4284883117 @default.
• W4309595582 cites W4293149707 @default.
• W4309595582 doi "https://doi.org/10.1158/2643-3230.bcd-22-0074" @default.
• W4309595582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36413381" @default.
• W4309595582 hasPublicationYear "2022" @default.
• W4309595582 type Work @default.
• W4309595582 citedByCount "11" @default.
• W4309595582 countsByYear W43095955822023 @default.
• W4309595582 crossrefType "journal-article" @default.
• W4309595582 hasAuthorship W4309595582A5000653097 @default.
• W4309595582 hasAuthorship W4309595582A5003948996 @default.
• W4309595582 hasAuthorship W4309595582A5007235827 @default.
• W4309595582 hasAuthorship W4309595582A5008019757 @default.
• W4309595582 hasAuthorship W4309595582A5008558372 @default.
• W4309595582 hasAuthorship W4309595582A5009175382 @default.
• W4309595582 hasAuthorship W4309595582A5011478481 @default.
• W4309595582 hasAuthorship W4309595582A5012849017 @default.

• next